Cardiomyopathy in children with mitochondrial disease: Prognosis and genetic background.


Journal

International journal of cardiology
ISSN: 1874-1754
Titre abrégé: Int J Cardiol
Pays: Netherlands
ID NLM: 8200291

Informations de publication

Date de publication:
15 Mar 2019
Historique:
received: 10 07 2018
revised: 30 12 2018
accepted: 03 01 2019
pubmed: 16 1 2019
medline: 18 12 2019
entrez: 16 1 2019
Statut: ppublish

Résumé

Cardiomyopathy is a reported indicator of poor prognosis in children with mitochondrial disease. However, the association between prognosis and the genetic background of cardiomyopathy in children with mitochondrial disease has yet to be fully elucidated. Of 137 children with mitochondrial disease whose genetic diagnosis was made between 2004 and 2018, 29 had mitochondrial cardiomyopathy (21%). After a median follow-up of 35 months, the overall survival rate was significantly lower in patients with cardiomyopathy than in those without (p < 0.001). Ten-year Kaplan-Meier estimates of overall survival were 18 and 67%, respectively. Among the 21 cardiomyopathy patients who died, two died within one month of birth (COQ4 in one patient, and COX10 in one patient), ten died within one year (BOLA3 in three patients, QRSL1 in two patients, large chromosomal deletions in two patients, MT-ATP6/8 in one patient, MT-TL1 in one patient, and TAZ gene in one patient), and nine died after one year (MT-ND5 in three patients, MT-TL1 in three patients, ACAD9 in one patient, KARS in one patient, and MT-TV in one patient). In the three patients with mitochondrial DNA mutations whose cardiac tissues were available, high heteroplasmy rates in the cardiac tissue were observed for m.8528T>C (90%, died at 2 months of age) and m.3243A>G (90 and 80%, died at 12 and 13 years of age, respectively). In children with mitochondrial disease, cardiomyopathy was common (21%) and was associated with increased mortality. Genetic analysis coupled with detailed phenotyping could be useful for prognosis.

Sections du résumé

BACKGROUND BACKGROUND
Cardiomyopathy is a reported indicator of poor prognosis in children with mitochondrial disease. However, the association between prognosis and the genetic background of cardiomyopathy in children with mitochondrial disease has yet to be fully elucidated.
METHODS AND RESULTS RESULTS
Of 137 children with mitochondrial disease whose genetic diagnosis was made between 2004 and 2018, 29 had mitochondrial cardiomyopathy (21%). After a median follow-up of 35 months, the overall survival rate was significantly lower in patients with cardiomyopathy than in those without (p < 0.001). Ten-year Kaplan-Meier estimates of overall survival were 18 and 67%, respectively. Among the 21 cardiomyopathy patients who died, two died within one month of birth (COQ4 in one patient, and COX10 in one patient), ten died within one year (BOLA3 in three patients, QRSL1 in two patients, large chromosomal deletions in two patients, MT-ATP6/8 in one patient, MT-TL1 in one patient, and TAZ gene in one patient), and nine died after one year (MT-ND5 in three patients, MT-TL1 in three patients, ACAD9 in one patient, KARS in one patient, and MT-TV in one patient). In the three patients with mitochondrial DNA mutations whose cardiac tissues were available, high heteroplasmy rates in the cardiac tissue were observed for m.8528T>C (90%, died at 2 months of age) and m.3243A>G (90 and 80%, died at 12 and 13 years of age, respectively).
CONCLUSIONS CONCLUSIONS
In children with mitochondrial disease, cardiomyopathy was common (21%) and was associated with increased mortality. Genetic analysis coupled with detailed phenotyping could be useful for prognosis.

Identifiants

pubmed: 30642647
pii: S0167-5273(18)34315-8
doi: 10.1016/j.ijcard.2019.01.017
pii:
doi:

Substances chimiques

DNA, Mitochondrial 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

115-121

Informations de copyright

Copyright © 2019. Published by Elsevier B.V.

Auteurs

Atsuko Imai-Okazaki (A)

Intractable Disease Research Center, Graduate School of Medicine, Juntendo University, Tokyo, Japan; Department of Genome Informatics, Osaka University Graduate School of Medicine, Osaka, Japan; Division of Genomic Medicine Research, Medical Genomics Center, National Center for Global Health and Medicine, Tokyo, Japan.

Yoshihito Kishita (Y)

Intractable Disease Research Center, Graduate School of Medicine, Juntendo University, Tokyo, Japan.

Masakazu Kohda (M)

Intractable Disease Research Center, Graduate School of Medicine, Juntendo University, Tokyo, Japan.

Yosuke Mizuno (Y)

Division of Analytical Science, Biomedical Research Center Hidaka Brunch, Saitama Medical University, Saitama, Japan.

Takuya Fushimi (T)

Department of Metabolism, Chiba Children's Hospital, Chiba, Japan.

Ayako Matsunaga (A)

Department of Metabolism, Chiba Children's Hospital, Chiba, Japan.

Yukiko Yatsuka (Y)

Intractable Disease Research Center, Graduate School of Medicine, Juntendo University, Tokyo, Japan.

Tomoko Hirata (T)

Laboratory for Comprehensive Genomic Analysis, RIKEN Center for Integrative Medical Sciences, Kanagawa, Japan.

Hiroko Harashima (H)

Department of Pediatrics, Saitama Medical University, Saitama, Japan.

Atsuhito Takeda (A)

Department of Pediatrics, Graduate School of Medicine, Hokkaido University, Hokkaido, Japan.

Akihiro Nakaya (A)

Department of Genome Informatics, Osaka University Graduate School of Medicine, Osaka, Japan.

Yasushi Sakata (Y)

Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Osaka, Japan.

Shigetoyo Kogaki (S)

Department of Pediatrics, Osaka University Graduate School of Medicine, Osaka, Japan.

Akira Ohtake (A)

Department of Pediatrics, Saitama Medical University, Saitama, Japan; Center for Intractable Diseases, Saitama Medical University Hospital, Saitama, Japan.

Kei Murayama (K)

Department of Metabolism, Chiba Children's Hospital, Chiba, Japan.

Yasushi Okazaki (Y)

Intractable Disease Research Center, Graduate School of Medicine, Juntendo University, Tokyo, Japan; Laboratory for Comprehensive Genomic Analysis, RIKEN Center for Integrative Medical Sciences, Kanagawa, Japan. Electronic address: ya-okazaki@juntendo.ac.jp.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH